Tapering a Beta-Blocker a Patient Feels Is Working, Against a Trial That Says It Doesn't
The trial evidence argues against beta-blockade for her kind of fainting, and may even argue it could make things worse. She started feeling better on it before anyone told her that, and stopping something that seems to be working is its own kind of decision.
E.R., a 44-year-old woman, has taught fourth grade for sixteen years, and fainted in front of her class during a fire drill last month — conscious again within seconds, embarrassed more than hurt, but rattled enough that she finally followed through on the cardiology referral her PCP had suggested twice before. She has had recurrent syncope for eight years, always with warning (lightheadedness, tunnel vision, sweating) before losing consciousness, and has tried the standard lifestyle measures — hydration, compression stockings, physical counterpressure maneuvers — with partial but incomplete benefit. After last month's episode her PCP started metoprolol before the cardiology visit could happen, and by the time she was seen she had already been on it for three weeks.
Her tilt-table test, performed as part of the referral workup, showed a clearly cardioinhibitory pattern — a brief period of significant bradycardia bordering on asystole accompanying her induced presyncope, distinct from a purely vasodepressor (blood-pressure-driven) pattern. That distinction matters directly to the metoprolol question: POST, the largest placebo-controlled trial of beta-blockade for vasovagal syncope, randomized 208 patients and found no benefit overall — but its randomization was prespecified to stratify at age 42, and the signal toward worse outcomes sat in the patients under 42, while those 42 and older trended toward benefit, a finding a successor trial, POST5, was built specifically to test. At 44 she falls on the older side of that line. Cutting the other way, beta-blockade in a patient whose reflex is already dominated by cardioinhibition could plausibly blunt the compensatory sympathetic response rather than help it, worsening the underlying tendency toward bradycardia rather than correcting it. She reports fewer presyncopal episodes since starting metoprolol three weeks ago, though three weeks and a single new medication is also a plausible setup for regression to the mean rather than a real drug effect.
At the cardiology/EP referral visit
POST is the largest placebo-controlled trial we have for beta-blockade in vasovagal syncope, and it was negative overall. I'll grant that its harm signal was concentrated in patients under 42 and that the 42-and-older stratum trended the other way, so at 44 the trial isn't straightforwardly against her. What is against her is the cardioinhibitory pattern specifically, which makes this worse mechanistically, not better; beta-blockade can blunt the compensatory response in exactly the reflex driving her bradycardia. I'd taper her off.
I hear the trial data, and I started this before the workup that would have told me her pattern was cardioinhibitory specifically. But she's telling us she's had fewer episodes over these three weeks, and I'm genuinely reluctant to remove something a patient reports is helping based on a population-level trial result in a single individual.
That reluctance is reasonable, and I don't think we need to resolve it by ignoring either the trial or her report — a supervised taper with a symptom diary lets us actually find out whether three weeks of improvement holds up once the drug is gone, rather than assuming either that it was the drug or that it wasn't. If symptoms recur and stay difficult to manage, dual-chamber pacing with rate-drop response is a real option later — she clears ISSUE-3's age criterion at 44, but that trial required asystole documented spontaneously on a loop recorder, and a tilt-induced pause isn't the same evidence. So it's worth having in view rather than reaching for now.
Supervised taper of metoprolol tartrate initiated over the following 4 weeks, with a structured symptom diary tracking presyncopal and syncopal episodes throughout.
Not resolved by the plan itself, and named directly as the open question the taper is meant to answer:
Her improvement likely reflected the lifestyle measures and time rather than metoprolol itself, consistent with POST's finding.
The trial-level evidence would not have generalized to her specific case, and metoprolol would be restarted with that finding documented for future reference.